Prognosis and clinical presentation of BRCA2-associated breast cancer
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
54 female breast cancer patients from 22 families with BRCA2 germ line mutations from Sweden and Denmark were compared with 214 age- and date of diagnosis-matched controls identified among breast cancer patients from South Sweden. At diagnosis, BRCA2-associated cases were more often node-positive (N+). OR=1.9 (95% confidence interval (CI)=1.0-3.6; P=0.036), and were more often clinical stage IV: OR=4.6 (95% CI=1.3-17; P=0.021) than the controls. Bilateral disease was also more common among the BRCA2-associated cases: OR=2. 4 (95% CI=1.1-5.3; P=0.027). Breast cancer-specific survival (BCSS) was significantly worse among the BRCA2-associated cases: RR=2.0 (95% CI=1.2-3.4; P=0.010). When stage was corrected for in a multivariate analysis, BCSS was no longer significantly worse for the BRCA2-associated cases: RR=1.6 (95% CI=0.85-3.1). The corresponding effect after correction for bilateral disease was: RR=1.8 (95% CI=1.0-3.1; P=0.034). The unfavourable prognosis in BRCA2-associated breast cancer seems, to a great extent, to be a consequence of the higher clinical stage at diagnosis. The increased presence of bilateral cancers appears to have less impact on survival in this group of hereditary breast cancer. Data presented here needs to be taken into account when counselling healthy carriers of BRCA2 germ line mutations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Localization of a Breast Cancer Susceptibility Gene, BRCA2 , to Chromosome 13q12-13
Wooster, R., Neuhausen, S. L., Mangion, J., Quirk, Y., Ford, D., Collins, N., Nguyen, K., Seal, S., Tran, T., Averill, D., et al. (1994) · Science · doi:10.1126/science.8091231 · Cited by 1,924
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds
Tavtigian, S. V., Simard, J., Rommens, J., Couch, F., Shattuck-Eidens, D., Neuhausen, S., Merajver, S., Thorlacius, S., Offit, K., Stoppa-Lyonnet, D., et al. (1996) · Nature Genetics · doi:10.1038/ng0396-333 · Cited by 839
Lakhani, S. R., Jacquemier, J., Sloane, J. P., Gusterson, B. A., Anderson, T. J., van de Vijver, M. J., Farid, L. M., Venter, D., Antoniou, A., Storfer-Isser, A., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.15.1138 · Cited by 707
Stratton, M. R. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10109-4 · Cited by 579
The tnm classification of malignant tumors
Tnm (1988) · Cited by 540
BRCA-associated breast cancer in young women.
Robson, M., Gilewski, T., Haas, B., Levin, D., Borgen, P., Rajan, P., Hirschaut, Y., Pressman, P., Rosen, P. P., Lesser, M. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1642 · Cited by 302 · cited 1×
“Some studies have reported that BRCA2-associated cancer occurs at a more advanced stage [8,10], on the basis that patients exhibit a more advanced axillary status [8] and a larger primary tumour size [10].”
BackgroundArmes, J. E., Trute, L., White, D., Southey, M. C., Hammet, F., Tesoriero, A. A., Hutchins, A., Dite, G. S., McCredie, M. R. E., Giles, G. G., et al. (1999) · PubMed · Cited by 269
Armes, J. E., Egan, A. J. M., Southey, M. C., Dite, G. S., McCredie, M. R. E., Giles, G. G., Hopper, J. L., & Venter, D. J. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981201)83:11<2335::aid-cncr13>3.0.co;2-n · Cited by 259
Research works printed but not linked: 1
- Armes, 1999, Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers, Cancer Res., 59, 2011
Cited by
Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers
Scheuer, L., Kauff, N., Robson, M., Kelly, B., Barakat, R., Satagopan, J., Ellis, N., Hensley, M., Boyd, J., Borgen, P., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1260 · Cited by 239
Robson, M. E., Chappuis, P. O., Satagopan, J., Wong, N., Boyd, J., Goffin, J. R., Hudis, C., Roberge, D., Norton, L., Bégin, L. R., et al. (2003) · Breast Cancer Research · doi:10.1186/bcr658 · Cited by 307
“Fewer studies have focused on BRCA2-related breast cancer [9,10].”
BackgroundBrekelmans, C. T. M., Tilanus-Linthorst, M. M. A., Seynaeve, C., vd Ouweland, A., Menke-Pluymers, M. B. E., Bartels, C. C. M., Kriege, M., van Geel, A. N., Burger, C. W., Eggermont, A. M. M., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.12.009 · Cited by 233
Goodwin, P. J., Phillips, K.-A., West, D. W., Ennis, M., Hopper, J. L., John, E. M., O'Malley, F. P., Milne, R. L., Andrulis, I. L., Friedlander, M. L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.0068 · Cited by 167
Prognosis of BRCA-associated breast cancer: a summary of evidence
Bordeleau, L., Panchal, S., & Goodwin, P. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0566-z · Cited by 135
Metadata
- Authors
- Loman, N., Johannsson, O., Bendahl, P.-O., Dahl, N., Einbeigi, Z., Gerdes, A.-M., Borg, Å., & Olsson, H.
- Affiliations
- Skåne University Hospital (SE)
- Uppsala University (SE)
- Sahlgrenska University Hospital (SE)
- Odense University Hospital (DK)
- Corresponding author
- Loman, N
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2000-07
- Volume
- 36
- Issue
- 11
- Pages
- 1365-1373
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W2121515794
- Cited by
- 46
- References
- 23
- Citations by year
- 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2018: 1 · 2016: 1 · 2015: 3 · 2014: 2 · 2012: 1
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- European Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Arvid Nilssons Fond
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- BRCA2, hereditary breast cancer, germline mutations, prognosis, breast cancer-specific survival, stage at diagnosis, node-positive disease, bilateral breast cancer, genetic counseling
- MeSH terms
- Adult, Aged, Aged, 80 and over, Breast Neoplasms, Denmark, Female, Humans, Middle Aged, Neoplasm Proteins, Neoplasm Staging, Pedigree, Regression Analysis, Risk Factors, Sweden, Transcription Factors, Survival Rate, Survival Analysis, Case-Control Studies, Germ-Line Mutation, BRCA2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognosis and clinical presentation of BRCA2-associated breast cancer. https://app.cochat.ai/papers/10.1016/s0959-8049(00)00098-8
- The paper
- Loman, N., Johannsson, O., Bendahl, P.-O., Dahl, N., Einbeigi, Z., Gerdes, A.-M., Borg, Å., & Olsson, H. (2000). Prognosis and clinical presentation of BRCA2-associated breast cancer. European Journal of Cancer. https://doi.org/10.1016/s0959-8049(00)00098-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.